Despite advancements, target identification in cancer faces several challenges:
Heterogeneity: Cancer is highly heterogeneous, meaning that different patients, and even different cells within a tumor, can exhibit different genetic and protein profiles. Complexity: The signaling pathways in cancer cells are complex and often redundant, making it difficult to identify targets that can be effectively inhibited. Drug Resistance: Cancer cells can develop resistance to targeted therapies, necessitating the identification of new targets.
